S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
NASDAQ:PLSE

Pulse Biosciences (PLSE) Stock Price, News & Analysis

$8.95
+0.55 (+6.55%)
(As of 12:34 PM ET)
Today's Range
$8.58
$9.09
50-Day Range
$7.80
$10.88
52-Week Range
$2.36
$13.62
Volume
44,727 shs
Average Volume
174,233 shs
Market Capitalization
$492.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PLSE stock logo

About Pulse Biosciences Stock (NASDAQ:PLSE)

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California.

PLSE Stock Price History

PLSE Stock News Headlines

Pulse Biosciences (PLSE) to Release Earnings on Thursday
PLSE Apr 2024 25.000 call
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
PLSE Oct 2024 17.500 call
PLSE Oct 2024 12.500 call
PLSE Jul 2024 2.500 put
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Pulse Biosciences Files 510(k) Submission With FDA For Its CellFX NsPFA
See More Headlines
Receive PLSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/30/2023
Today
3/28/2024
Next Earnings (Confirmed)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PLSE
Fax
N/A
Employees
61
Year Founded
N/A

Profitability

Net Income
$-58,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$700,000.00
Book Value
($0.06) per share

Miscellaneous

Free Float
16,690,000
Market Cap
$462.67 million
Optionable
Optionable
Beta
1.69
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Robert W. Duggan (Age 79)
    Executive Chairman
  • Mr. Kevin P. Danahy (Age 53)
    President & CEO
    Comp: $393.25k
  • Mr. Darrin R. Uecker (Age 58)
    CTO & Director
    Comp: $487.24k
  • Mr. Mitchell E. Levinson (Age 64)
    Chief Strategy Officer
    Comp: $361.34k
  • Dr. Richard Nuccitelli Ph.D.
    Chief Science Officer
  • Mr. Kenneth B. Stratton Esq. (Age 55)
    J.D., General Counsel & Corporate Secretary
  • Ms. Patty Perla
    Vice President of Human Resources
  • Mr. David Danitz
    Senior Vice President of Engineering
  • Dr. Gansevoort Dunnington M.D.
    Chief Medical Officer
  • Dr. Niv Ad M.D.
    Chief Science Officer of Cardiac Surgery

PLSE Stock Analysis - Frequently Asked Questions

How have PLSE shares performed in 2024?

Pulse Biosciences' stock was trading at $12.24 at the start of the year. Since then, PLSE shares have decreased by 26.9% and is now trading at $8.95.
View the best growth stocks for 2024 here
.

When is Pulse Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our PLSE earnings forecast
.

How can I listen to Pulse Biosciences' earnings call?

Pulse Biosciences will be holding an earnings conference call on Thursday, March 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences, Inc. (NASDAQ:PLSE) released its quarterly earnings results on Thursday, March, 30th. The company reported ($0.24) EPS for the quarter. The firm had revenue of ($0.01) million for the quarter.

What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO?

2 employees have rated Pulse Biosciences Chief Executive Officer Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among the company's employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pulse Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), Enphase Energy (ENPH) and Novavax (NVAX).

When did Pulse Biosciences IPO?

Pulse Biosciences (PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.

Who are Pulse Biosciences' major shareholders?

Pulse Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.19%), Vanguard Group Inc. (1.19%), Griffin Asset Management Inc. (0.47%), Northern Trust Corp (0.33%), Westside Investment Management Inc. (0.06%) and Nuveen Asset Management LLC (0.05%). Insiders that own company stock include Kevin Patrick Danahy, Mitchell E Levinson and Robert W Duggan.
View institutional ownership trends
.

How do I buy shares of Pulse Biosciences?

Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PLSE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners